Liver Transplantation Center, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, 37 Guoxue Lane, Wuhou District, Chengdu, 610041, Sichuan, China.
Key Laboratory of Green Chemistry and Technology of Ministry of Education, College of Chemistry, Sichuan University, Chengdu, 61064, Sichuan, China.
Surg Endosc. 2024 Nov;38(11):6938-6947. doi: 10.1007/s00464-024-11295-8. Epub 2024 Sep 29.
This study aimed to investigate the feasibility and efficacy of near-infrared fluorescence-guided laparoscopic anatomical hepatectomy (LAH) using a novel indocyanine green (ICG)-human serum albumin complex (HSA) in patients with hepatocellular carcinoma.
Clinical data of hepatocellular carcinoma patients who underwent ICG-HSA fluorescence-guided LAH at our center from January 2024 to April 2024 were prospectively collected and analyzed. Ultraviolet absorption spectroscopy was used to test the absorption and stability of ICG-HSA complex solutions under different conditions. After determining the optimal ratio, the complex was administered intravenously during surgery to perform negative staining via Glissonean pedicle isolation. LAH was performed along the fluorescence-demarcated boundaries.
Thirty-one patients were included (24 men; mean age, 54.61 ± 13.54 years). The median maximum tumor diameter was 2.80 (interquartile range [IQR], 2.00-4.00) cm. S8 segmentectomy (22.6%) and right posterior segmentectomy (19.4%) were the most common resections performed. Successful fluorescence negative staining was achieved in all patients using ICG and HSA at a 1:6 molar ratio at room temperature. Mean operation time was 297.58 ± 85.53 min, Median intraoperative blood loss was 100.0 mL (IQR, 50.0-200.0). The median surgical margin distance was 0.90 cm (IQR, 0.40-1.50). The postoperative complication rate was 45.2% (35.5% Clavien-Dindo grade I and 9.7% grade II). The median length of hospital stay was 5.0 days (IQR, 4.0-5.0).
ICG-HSA-assisted LAH is safe and feasible. Compared with free ICG, the novel ICG-HSA complex exhibits better optical properties and in vivo stability, which can improve the accuracy of intraoperative liver segment localization and optimize the anatomical dissection plane. It has the potential to become an ideal fluorescent imaging agent for anatomical hepatectomy.
本研究旨在探讨新型吲哚菁绿(ICG)-人血清白蛋白(HSA)复合物在肝细胞癌患者中应用于近红外荧光引导腹腔镜解剖性肝切除术(LAH)的可行性和疗效。
前瞻性收集 2024 年 1 月至 2024 年 4 月在我院行 ICG-HSA 荧光引导 LAH 的肝细胞癌患者的临床资料。采用紫外吸收光谱法检测不同条件下 ICG-HSA 复合物溶液的吸收和稳定性。确定最佳比例后,术中静脉给予复合物,通过 Glissonean 蒂隔离进行负染。沿荧光标记边界行 LAH。
共纳入 31 例患者(男 24 例;平均年龄 54.61±13.54 岁)。最大肿瘤直径中位数为 2.80cm(四分位距 [IQR],2.00-4.00cm)。行 S8 段切除术(22.6%)和右后段切除术(19.4%)者最常见。室温下 ICG 与 HSA 以 1:6 摩尔比混合可实现所有患者的成功荧光负染。平均手术时间为 297.58±85.53min,中位术中出血量为 100.0ml(IQR,50.0-200.0ml)。手术切缘距离中位数为 0.90cm(IQR,0.40-1.50cm)。术后并发症发生率为 45.2%(35.5%Clavien-Dindo Ⅰ级,9.7%Ⅱ级)。中位住院时间为 5.0 天(IQR,4.0-5.0 天)。
ICG-HSA 辅助 LAH 是安全可行的。与游离 ICG 相比,新型 ICG-HSA 复合物具有更好的光学特性和体内稳定性,可提高术中肝段定位的准确性,优化解剖性肝切除平面。有望成为解剖性肝切除术的理想荧光成像剂。